Copy Link Print Information

Tifcemalimab

(Synonyms: JS004; Icatolimab)
고객리뷰

Based on 1 Customer Validation

Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • 보관:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Tifcemalimab
  • Experimental Validation Results for Tifcemalimab
  • Tifcemalimab Chemical Structure
    Tifcemalimab Chemical Structure
CAS No.: 2236068-83-8
사이즈
가격
재고
수량
Amount: USD 0.00
Please select quantity
or
or

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Tifcemalimab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
주변의 대리점 찾기 Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • 순도&문서
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products
Keywords
100 mg

견적 받기 해외재고보유

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress 로그인
Register
Sign in to MedChemExpress
회원가입

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Immobilized hu-BTLAECD-his can bind Tifcemalimab. The EC50 for this effect is 16.01 ng/mL.

  • Tifcemalimab Chemical Structure
    1/16
  • Tifcemalimab
  • Immobilized hu-BTLAECD-his can bind Tifcemalimab. The EC50 for this effect is 16.01 ng/mL.